Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial
about
Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapyOptions for empagliflozin in combination therapy in type 2 diabetes mellitusSystematic review and meta-analysis of efficacy and safety of combinational therapy with metformin and dipeptidyl peptidase-4 inhibitorsEfficacy and safety of canagliflozin among patients with type 2 diabetes mellitus: A systematic review and meta-analysisCanagliflozin Treatment in Patients with Type 2 Diabetes MellitusSodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetesTreating the elderly diabetic patient: special considerationsEarly diabetic nephropathy in type 1 diabetes: new insightsCardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-AnalysisCanagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 DiabetesEfficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozinRisk of diarrhea in patients with type 2 diabetes mellitus treated with sitagliptin: a meta-analysis of 30 randomized clinical trialsBenefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-AnalysisCardiovascular effects of dipeptidyl peptidase-4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review.Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis.Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studiesStandard and Novel Treatment Options for Metabolic Syndrome and Diabetes MellitusNovel and emerging diabetes mellitus drug therapies for the type 2 diabetes patientCanagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data.Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitusLong-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: A meta-analysis.Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor.Update on developments with SGLT2 inhibitors in the management of type 2 diabetesA clinical perspective of canagliflozin in the management of type 2 diabetes mellitus.Canagliflozin: a novel treatment option for type 2 diabetes.Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system.Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options.Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetesEfficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trialCanagliflozin: effects in overweight and obese subjects without diabetes mellitus.Cardiovascular safety profile of currently available diabetic drugs.Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agentsEfficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study.Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis.Comparative Efficacy of Adding Sitagliptin to Metformin, Sulfonylurea or Dual Therapy: A Propensity Score-Weighted Cohort Study.
P2860
Q26739888-65B24236-14DE-4562-BACE-DA68B5714075Q26745771-457A4CDB-229D-4E08-B180-7B6A46904C0FQ26772081-90536D39-B46D-49E4-940E-51091EA3865EQ26773558-70E33DAC-D95B-4539-A444-1B336F84DF56Q26777529-98EB015C-F734-47B3-8612-E92E34892B6CQ26864336-C95BE010-5B32-4BCA-A866-A5FEF40FF17DQ26995176-60321847-6219-4F80-8BB0-D01FF8CAF163Q27021632-E814DFE0-37BF-4ED8-90C6-96DBE2117968Q28071764-307D6C6F-9EE7-4A01-BF5B-FC0DCAD64D74Q28072339-B9DF6862-6EE8-4DDD-A77E-AB80CF64DFBEQ28250844-8A05E2ED-9178-4F8D-B9F2-0647DCFDD6B2Q28544980-3945400C-80E2-4ED1-B146-C7EA1A86E365Q28553482-F4FDBD55-F610-479F-BF49-7B416B88297FQ30241808-D80A0451-E938-4061-8098-A2E343C1FC3DQ30248634-306C4518-B5E3-4C72-BE2D-B151F1616565Q32186373-75FFB220-BF1B-44CD-A87A-A54A8F6B2231Q33613143-745E69AC-7F2F-45A9-B50A-61980867EC70Q33618721-E0C38067-5687-41A9-9EBC-AA19D6F43ED6Q33759570-B01AB77F-E982-480E-80FE-84181884D931Q33759610-EF4D48FD-ED29-4D30-A5CF-C97110A9DAA9Q33781497-69066B91-70FF-47C0-A106-DD4D4FA4DB7EQ33871321-1E8C9DB6-DEAB-484D-8FED-2B44A89A5C47Q33885732-D535EE16-F341-4BD0-BF4D-59DA7CC77CBEQ34105064-44193737-EAFF-45EF-AC6B-6281F6B5E7A0Q34161881-B16E6D16-960E-4EEF-BEA0-2CB865B2BFE5Q34198692-4C38A4A0-9218-44EE-96EF-2BA8DF3D9FC4Q34264365-348A3193-A993-4675-983B-449CD1A48EDAQ34388544-236CACEE-C03D-4193-9E2C-BE4EFCD1E7C9Q34457919-AB792703-A2DA-4AC2-8AFC-EE6C399F14D4Q34503796-FC198CD4-762E-4C2B-8C5B-31F2CFA905D6Q34543009-28D7A833-5857-42AF-84C0-7F436BB84B33Q34563587-8F1D35B0-FCD6-480C-A28D-0BC9B4A59D9AQ34699217-727FFD12-BE1E-4F6A-9A0F-07E8084EDF6FQ34804900-C2975C3D-3CBC-4A97-82CE-79E8D22FDA19Q34851219-0143E092-CCF7-4B90-9FD3-B2FCC86E5826Q34971736-FB7A39E9-CF60-4333-B9E0-B32996D63095Q34973750-16B1CBAD-43E4-488B-838A-61DE7F60BB09Q35192198-861D67BA-29AB-44B8-802F-C65548FFCEF4Q35225256-BD4BA90B-5435-4A21-9786-793D603DFB4FQ35772558-8AE1E171-C0CE-4EEB-8CC0-C6182C84D209
P2860
Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 April 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Canagliflozin compared with si ...... ea: a 52-week randomized trial
@en
Canagliflozin compared with si ...... a: a 52-week randomized trial.
@nl
type
label
Canagliflozin compared with si ...... ea: a 52-week randomized trial
@en
Canagliflozin compared with si ...... a: a 52-week randomized trial.
@nl
prefLabel
Canagliflozin compared with si ...... ea: a 52-week randomized trial
@en
Canagliflozin compared with si ...... a: a 52-week randomized trial.
@nl
P2093
P2860
P921
P356
P1433
P1476
Canagliflozin compared with si ...... ea: a 52-week randomized trial
@en
P2093
Gary Meininger
Guntram Schernthaner
Jacqueline Yee
Jorge L Gross
Masato Kawaguchi
Michael Guarisco
William Canovatchel
P2860
P304
P356
10.2337/DC12-2491
P407
P577
2013-04-05T00:00:00Z